Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A Study to Assess THN391 in Subjects With Alzheimer's Disease — Stella

Home/Alzheimer Disease, Early Onset/A Study to Assess THN391 in Subjects With Alzheimer's Disease

View on ClinicalTrials.gov

Recruiting

Back to Alzheimer Disease, Early Onset trials

A Study to Assess THN391 in Subjects With Alzheimer's Disease

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(4 sites)

Netherlands

Amsterdam UMC, Amsterdam, New Hampshire

CTC-Netherlands, Groningen

United Kingdom

Scottish Brain Sciences, Edinburgh

University College London Hospitals, London

Key details

Phase

Early testing

Sponsor

Therini Bio, Inc.

Enrollment target

~15 participants

Started

July 2025

Primary completion

May 2026

Age range

65 Years – 85 Years

Last updated September 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.